WHO ICTRP trial
Safety and Efficacy of MCA-derived Mesenchymal Stromal Cell Therapy in Renal…
NL-OMON53310 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON53310 |
|---|---|
| Public title | Safety and Efficacy of MCA-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients: The Nereid Study* |
| Scientific title | Safety and Efficacy of MCA-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients: The Nereid Study* - MCA-derived MSC therapy in renal transplant recipients |
| Primary sponsor | Leids Universitair Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Netherlands |
| Conditions | BPAR rejection transplanted kidney;10038430 |
| Interventions | All patients will receive steroids according to the LUMC protocol and induction treatment with basiliximab at day 0 and 4 (20 mg intravenously). Patients will receive either 1 or 2 doses of 2x10^6 (+/- 10%) MCA-derived MSC/kg - the first at… |
| Registration date | Dec 28, 2022 |
| Target size | 16 |
| Secondary IDs | 2022-004168-11;NL83484.000.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: